This issue describes Russian commercial pharmacy market in April 2007.
Russian Pharmaceutical Market. June 2007 ( *.pdf file 522.66 Kb )
SUMMARY:
Drugs commercial market value increased by 17.5% (in dollars) in the period of January-April 2007 compared to that of 2006 and amounted to $1751 mln.
In April 2007 drugs commercial market value (in pharmacy purchase prices) decreased by 5.1% in April compared to March 2007 and amounted to $453 mln (VAT included); however it is 20% higher than in April 2006.
The weighted average price per drug unit on Russian commercial market increased by 1.12% in April 2007 and amounted to 40.37 rubles ($1.56).
According to Laspeyres index prices of the commercial market decreased by 0.3% in rubles in April compared to March 2007; and increased by 0.7% in dollars. For the TOP-100 leading brands of 2006, prices increased by 0.7% in dollars and decreased by 0.1% in rubles.
Drugs consumption structure did not changed in April 2007 compared to March 2007. The average unit price decreased by 6% for expensive drugs (priced at 500 rbl. per unit) in April 2007 compared to April 2006. In other price segments (under 500 rbl. per unit) there were not any significant changes.
In April 2007, domestic and imported drugs ratio in value terms stayed the same as the year before and amounted to 24% and 25% correspondingly. In unit terms domestic drugs share decreased by 2% in April 2007 compared to that of 2006 and amounted to 67%.
In the 1st quarter 2007, proportion of Rx and OTC drugs stayed almost the same as the year before. Rx drugs cover 60% of commercial sales value (59% in April 2006). In unit terms Rx drugs share amounted to 38% in April 2007, which is 3% higher than the year before.
TOP-10 drugs manufactures of April 2007 changed in comparison to March. Pharmstandard company’s share decreased by 1.35% in value terms. Sanofi-Aventis increased its share by 0.31%. Thus Sanofi-Aventis became the leader. Berlin-Chemie /A.Menarini/ stayed at the 3rd position.
Pharmstandard’s sales value increased by 47.3% compared to the previous year; it covered 4.1% share in April 2007 (2.8% in April 2006).
The 1st one among the TOP-20 leading drug trade names of April 2007 is Actovegin. Arbidol having been the leader from September 2006 moved to the 2nd position of due to seasonal decline in anticatarrhal medications sales. However it is still doubtless leader within its group.
Viagra slightly increased in sales (by 8%) and became 3rd in the TOP-20. Anticatarrhal medications continued to decrease in share in April 2007. Coldrex showed maximum one (-36 rating lines).
For the period of January-April 2007 Russian NS (nutritional supplements) pharmacy market value increased by 4.8% compared to that of 2006 and amounted to $112 mln.
NS market value decreased from $32.3 mln in March to $29.7 mln in April 2007 (-7.9%). Compared to April 2006 it increased by 6.2% in value terms.
The weighted average cost per NS unit is $1.87 (48 rubles) in April 2007 which is 2% lower than in March.
Capilar (by Diod) leads the TOP-20 NS trade names. Bilberry-Forte and Ovesol (both by Evalar) are the 2nd and the 3rd ones. AlphaVIT (by Akva-MDT/Akvion) left TOP-3 due to 33.6% share decrease. It is 4th in April 2007.
TOP-3 NS manufacturers on the NS commercial market stayed the same in April 2007.
All market reviews by DSM Group are available on the page Analytics.
